Hepatitis B Reactivation in Biologic‐Treated Moderate‐to‐Severe Psoriasis: A Real‐World Cohort Study With 534 Patient‐Years of Follow‐Up

Documenti analoghi

• Serum C‐Reactive Protein as a Potential Indicator for Screening Fecal Calprotectin in Patients With Moderate‐to‐Severe Hidradenitis Suppurativa: A Cross‐Sectional Cohort Study
  di: Neslihan Demirel Öğüt, et al.
  Pubblicazione: (2025)
• Deucravacitinib in Psoriasis: Evidence, Gaps, and Place in Therapy
  di: Ece Gokyayla, et al.
  Pubblicazione: (2025)
• Dermatologists' Way of Informative Content About Dermatology and Cosmetology on Social Media
  di: Simge Ünal, et al.
  Pubblicazione: (2025)
• Evaluation of serial QuantiFERON ‐ TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti‐ IL ‐17 treatment (secukinumab and ixekizumab): Real‐world data from a tuberculosis‐endemic country
  di: Ece Erbağcı, et al.
  Pubblicazione: (2024)
• Real‐World Experience of Secukinumab Treatment in Patients with Moderate‐to‐Severe Plaque Psoriasis in Greece: 3‐Year Interim Results of the SERENA Study
  di: Dimitrios Ioannides, et al.
  Pubblicazione: (2024)